Top Page
Corcept Therapeutics
(NASDAQ:CORT)
Corcept Therapeutics (CORT) vs. SPDR S&P 500 ETF (SPY)
Corcept Therapeutics Business Overview & Revenue Model
Corcept Therapeutics Earnings Call Summary
Corcept Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 716.08M | 675.04M | 482.38M | 401.86M | 365.98M | 353.87M |
| Gross Profit | 704.42M | 664.16M | 475.89M | 396.47M | 360.70M | 348.29M |
| EBITDA | 103.84M | 136.95M | 108.32M | 113.89M | 127.95M | 130.44M |
| Net Income | 132.52M | 139.73M | 106.14M | 101.42M | 112.51M | 106.01M |
Balance Sheet | ||||||
| Total Assets | 801.72M | 840.55M | 621.52M | 583.43M | 423.76M | 571.73M |
| Cash, Cash Equivalents and Short-Term Investments | 342.23M | 383.33M | 368.22M | 436.62M | 335.81M | 476.89M |
| Total Debt | 6.61M | 6.94M | 151.00K | 1.14M | 526.00K | 2.55M |
| Total Liabilities | 165.93M | 160.96M | 114.81M | 81.59M | 47.95M | 48.39M |
| Stockholders Equity | 635.79M | 679.59M | 506.70M | 501.84M | 375.81M | 523.34M |
Cash Flow | ||||||
| Free Cash Flow | 180.28M | 195.90M | 126.90M | 119.91M | 167.42M | 150.73M |
| Operating Cash Flow | 182.20M | 198.07M | 127.04M | 120.32M | 167.89M | 151.97M |
| Investing Cash Flow | -41.44M | -177.60M | 90.91M | -114.33M | 136.13M | -119.26M |
| Financing Cash Flow | -168.39M | -28.35M | -148.72M | -17.28M | -302.59M | 12.21M |
Corcept Therapeutics Technical Analysis
Corcept Therapeutics Risk Analysis
Corcept Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.74B | 65.38 | 21.42% | ― | 25.71% | 4.48% | |
| ― | $8.27B | ― | -10.84% | ― | 4.52% | -205.13% | |
| ― | $6.74B | ― | -280.68% | ― | 69.83% | 22.16% | |
| ― | $7.56B | ― | -1334.54% | ― | 53.55% | 30.87% | |
| ― | $11.00B | ― | -46.61% | ― | -100.00% | -23.49% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $5.95B | ― | -29.71% | ― | 74.86% | -13.23% |
Corcept Therapeutics Corporate Events
On October 10, 2025, Corcept Therapeutics announced the termination of its Distribution Services Agreement with Optime Care, effective January 8, 2026. This decision follows a previous notification in June 2025, where Corcept exercised its rights to end Optime’s exclusivity in providing pharmacy services for its medications, impacting the company’s distribution strategy and potentially altering its market dynamics.
The most recent analyst rating on (CORT) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
On October 10, 2025, Gillian Cannon, Ph.D., resigned from the Board of Directors of Corcept Therapeutics Incorporated. Her resignation was not due to any disagreements with the company. The company has expressed gratitude for her contributions. In conjunction with her resignation, Dr. Cannon will continue to provide consulting services to the Board until the 2026 stockholders meeting, receiving a monthly fee and maintaining her stock options’ vesting schedule.
The most recent analyst rating on (CORT) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
On September 10, 2025, Corcept Therapeutics announced that the FDA has accepted its New Drug Application for relacorilant, intended for treating patients with platinum-resistant ovarian cancer. This acceptance, based on positive Phase 2 and 3 trial results, marks a significant step towards offering a new treatment option for this challenging condition, with the FDA assigning a PDUFA date of July 11, 2026. Relacorilant, which has shown improved progression-free and overall survival rates without increasing safety risks, could potentially redefine treatment for this form of cancer.
The most recent analyst rating on (CORT) stock is a Buy with a $79.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Corcept Therapeutics is currently recruiting for a Phase 1 clinical study titled ‘Evaluation of Miricorilant on Liver Fat in Patients With MASLD.’ The study aims to assess the effect of Miricorilant on hepatic lipids in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH). This research is significant as it targets a prevalent liver condition with limited treatment options.
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension in the United States of America (MOMENTUM).’ The study aims to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN). This research is significant as it could reveal important insights into the relationship between eHC and rHTN, potentially leading to better management strategies for affected patients.
Corcept Therapeutics is conducting a Phase 1 study titled ‘Evaluation of Miricorilant on Liver Fat in Patients With MASLD.’ The study aims to assess the effect of Miricorilant on hepatic lipids in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH). This research is significant as it targets a condition linked to metabolic disorders, offering potential therapeutic advancements.
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)’ to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) in the United States. This study aims to enroll approximately 1,000 patients across 45 sites, focusing on identifying eHC in a specific patient population, which could have significant implications for treatment approaches in resistant hypertension.
Corcept Therapeutics is currently recruiting participants for a Phase 2 clinical study titled A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA). The study aims to evaluate the efficacy and safety of an intermittent dosing regimen of relacorilant combined with nab-paclitaxel and bevacizumab in patients with advanced ovarian cancer, highlighting its potential significance in improving treatment outcomes.
Corcept Therapeutics’ recent earnings call painted a picture of robust growth tempered by some operational challenges. The company reported impressive revenue growth and significant advancements in clinical trials, indicating a strong commercial outlook. However, these positive developments were somewhat overshadowed by supply chain issues and ongoing patent litigation, resulting in a mixed overall sentiment.
Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company focused on developing medications that modulate the effects of cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company is known for its product Korlym, used in the treatment of hypercortisolism, and is headquartered in Redwood City, California.
On July 31, 2025, Corcept Therapeutics announced its financial results for the second quarter of 2025, reporting a revenue increase to $194.4 million from $163.8 million in the same quarter of 2024. Despite a slight decrease in net income, the company highlighted significant clinical development milestones, including the publication of results from its CATALYST and ROSELLA studies and ongoing New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Corcept’s advancements in clinical trials and strategic stock repurchases indicate a robust growth trajectory and potential leadership in cortisol modulation therapies.
The most recent analyst rating on (CORT) stock is a Buy with a $67.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Corcept Therapeutics is conducting an extension study titled ‘An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome.’ The study aims to evaluate the long-term safety of relacorilant, a selective glucocorticoid receptor antagonist, in patients with endogenous Cushing syndrome who have completed a prior Corcept-sponsored study. This research is significant as it explores the potential for continued treatment benefits in this patient population.
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM).’ The study aims to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN), enrolling approximately 1000 patients across 45 sites in the United States. This research is significant as it could provide insights into the relationship between eHC and rHTN, potentially influencing future treatment approaches.
Corcept Therapeutics is conducting a Phase 2 study titled ‘A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS).’ The study aims to assess the safety and efficacy of dazucorilant in treating Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.